跳到主要內容

Pickering Grant 的 Form 4 申報

Vaxcyte, Inc.(PCVX),2024/4/3 申報

申報編號
0001415889-24-009995
申報時間
2024/4/3
交易日
2024/4/1
申報延遲
2 天
10b5-1 計畫
有勾選

這份申報列了 5 筆非衍生性交易。公開市場賣出合計 $17.5 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Pickering GrantCIK 0001258693董事、高階主管(執行長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2024/4/1Common StockS賣出處分−984$66.52F2−$65,455.68147,686間接
2024/4/1Common StockS賣出處分−324$67.27F4−$21,795.48147,362間接
2024/4/1Common StockS賣出處分−890$66.45F5−$59,140.5147,780間接
2024/4/1Common StockS賣出處分−415$67.24F7−$27,904.6147,365間接
2024/4/1Common StockS賣出處分−3$68.10−$204.3147,362間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F2

The price reported is a weighted-average price. The shares were sold at prices ranging from $66.05 to $66.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

F4

The price reported is a weighted-average price. The shares were sold at prices ranging from $67.14 to $68.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

F5

The price reported is a weighted-average price. The shares were sold at prices ranging from $66.02 to $66.87. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

F7

The price reported is a weighted-average price. The shares were sold at prices ranging from $67.025 to $67.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)